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THE IMMUNOLOGICAL AND INFECTIOUS SEQUELAE OF
THE ACQUIRED IMMUNE DEFICIENCY SYNDROME
BY ZANVIL A. COHN AND RALPH M. STEINMAN
On 17-18 May, 1988, ameetingat The RockefellerUniversity Conference Center
in Mount Kisco, New York, brought together a small group ofexperts in the field
ofAIDS and related disciplines. Their purpose was to consider central issues in the
pathogenesis, immunology, and therapyofHIV infections in aformat that encour-
aged free discussion. There were no formal presentations. Session chairmen, who
were largely responsible for the success ofthe meeting, posed a series ofquestions,
organized discussants, and maintained an active and focused dialogue. Since the
meetingwas restricted in size, we thought it appropriate to review the four sessions
for a wider audience.
Session I.- Pathogenesis. Chairmen: Malcolm A. Martin and Bernard Fields
A. Modes ofEntry
1. State of Transmissable Virus.
￿
Acentral question concerning the transmissibility
ofHIV infection is whether the virus is free and/or intracellular. While -30% of
serum samples contain low titers of virus, the cellular elements of blood contain
levels that exceed those of serum 100-fold. The types of cells that are infected in
blood are not known. Ifthe virus is free, does it exist in the form of immune com-
plexes in seropositive individuals who demonstrate abroad range ofanti-viral anti-
bodies? Would not suchimmune complexes be rapidlycleared from the circulation?
Such considerations suggest that free virus may not be a significant factor in trans-
mission. Nevertheless, theinfectivity ofplasma products such asFactor VIII no doubt
stems from the presence of free virus.
Similar considerationspertain tothe infectivity ofotherbodyfluids suchas semen,
saliva, and vaginal secretions. In the case of semen, which contains appreciable
amounts of virus, virus can be detected in 0.01-5% of cells, which seem to be
mononuclear leukocytes. Similarly, the examination ofthe testis by in situ hybrid-
ization reveals the presence ofviral mRNA primarily in infiltrating leukocytes. It
is not known whethermature spermatozoa contain virus norwhat the contribution
ofprostatic cells and secretions are to the total virus load ofsemen. Both vaginal
fluids and saliva contain low titers ofvirusand thisis predominantlycell associated -
most likely with hematogenously derived whitecells. Onlyin the cerebrospinal fluid
are there relatively high titers of free virus.
Investigators analyzing these questions have been hampered by the lack ofsuit-
able, sensitive bioassays for infectious virus. Most agree that live virus constitutes
only a small fraction of total virions present in blood and body fluids. This may,
inpart, be the result ofsuch antiviral agents in body fluids as cell-derived hydrogen
peroxide, peroxidases, and halide ions.
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2. Transport across Mucosal Barriers.
￿
The deposition of virus in the genitourinary
or gastrointestinal tracts in either the free, complexed, or intracellular state may
lead to transmission. The likelihood oftransmission is enhanced if preexisting le-
sions are present oriftrauma is associatedwith the sexual act. Epidemiologists now
consider that preexisting breaks in surface barriers and thelackofcircumcision facili-
tate viral passage. The lesions may be in the form of genital ulcers secondary to
sexually transmitted diseases such as syphilis, chancroid, or herpes. The high inci-
denceofheterosexual transmission in CentralAfrica maybethe result ofsuch factors.
Promiscuity and receptive anal intercourse enhance the incidence oftransmission.
The interaction of free virus or HIVinfected cells with epithelial cells is poorly
understood. Whether or not there are epithelial receptors that recognize virus sur-
face glycoproteins, and/or infected T cells and monocytes, is unknown. IgA anti-
bodies against viral components, which might be present on the surface ofrespira-
tory andgastrointestinal epithelia could play a role in either neutralizing orenhancing
infectivity.
In addition to epithelial cells there are other cellular elements with membranous
processes that extend to or near the lumen of colon, vagina, or respiratory tract.
Results with newer immunocytochemical reagents indicate that cells with the sur-
face phenotype ofmononuclear phagocytes are present in large numbers. Strongly
MHC class II-positive cells ofthe dendritic and Langerhans series are also widely
distributed, and both cell lineages are thought to be susceptible to viral entry and
replication. There is in situ hybridization evidence that enterochromaffin cells of
the intestinalcrypts ofseropositive menwith chronicdiarrhea are productivelyinfected.
The low efficiency of viral transmission via sexual acts, calculated as less than
1 in 60, makes it difficult to study the factors involved in human disease except for
retrospective analysis. For this reason investigatorshave been strivingto develop an-
imal models ofHIV infection. Theuse ofchimpanzees fortransmission and vaccine
trials is notideal. This primate develops antibodies and is permissive forviral repli-
cation, but has failed to develop an immunodeficiency syndrome to date. In con-
trast, the rhesus monkey does develop anAIDS-like syndrome, succumbing to similar
secondary microbial invaders when infected with the related SIV agent. Whereas
the chimpanzee is now an endangered species and present in only small numbers,
largebreedingcolonies ofrhesus monkeys are nowmaintainedin U. S. primatecenters
and appear to represent the species of choice.
3. Initial Targets of Virus Replication.
￿
At least three bone marrow-derived, blood-
borne cell types are considered toharbor HIV. These areT lymphocytes, mononuclear
phagocytes (monocytes, macrophages), and dendritic-Langerhans cells. The loss of
helper type, CD4+ T cells is associated with severe immunological deficiency, but
a puzzling aspect of pathogenesis is the very low incidence of CD4+ cells that are
productively infected. This is usually <0.01'Io ofCD4+ cells in the peripheral blood,
as shown by in situ hybridization techniques. Infection by HIV is best evaluated
bythe culture ofblood leukocytes in thepresence ofthe plant lectin PHA. Reverse-
transcriptase activity and ELISA+ glycoprotein antigens, such as p24, appear after
a week or two in vitro. The recent development of the polymerase chain reactions
(PCR) should provide a more sensitive and rapid technique forvirus identification.
Thecombined useofcarefully separatedcellpopulations, alongwith the PCR, shouldCOHN AND STEINMAN
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yield important information on the types of cells that carry HIV and disease
pathogeneasis.
Considerable interest hasfocused recently on blood monocytes and tissue macro-
phages as cells that both harbor and release infectious virions. In most instances,
one hasto co-culture blood-adherent monocyteswith lectin-stimulated T blasts from
uninfected controls to detect virus. However, monocyte cultures can be contami-
nated with small numbers of CD4+ T cells and dendritic cells, and this complicates
analysis of viralorigin. Recent evidence suggests that monocytes cultured with growth
factors contain large numbers of intracellular virions (within membrane-bound in-
tracellular vacuoles), but release few to the environment. Whether these particles
are infectious and what precludes their passage across the plasma membrane are
questions for the future. It is the general experience that as the disease progresses
to symptomaticAIDS, virusis more consistently identified in cultures ofbloodmono-
nuclear cells.
More recent reports implicate dendritic cells and Langerhans' cells as being pri-
mary cells in the infectious process. We await more detailed analysis with highly
purified populations, obtained throughout the course of the disease. These potent
accessory cells forT cell replication represent an important element of cell-mediated
immunity, and their infection by virus could compromise T cell function and/or
represent a pathway for bringing HIV to T cells. Interesting new data from mouse
transfectants, carrying a 5'-LTRCATconstruct, demonstratevery high levels ofCAT
expression in Langerhans'cells oftail skin. Similarly, Langerhans-like cells obtained
from the bronchoalveolar lavage ofpatients with thepulmonary form ofeosinophilic
granuloma can express very high levels of reverse transcriptase after infection with
exogenous HIV.
Spread Within the Host
1. The Syndrome ofPrimary Infection and Early Replication.
￿
Recent evidence from
world-wide sourcesindicates that theearly, extensive replication with HIVvirus leads
to adefined syndrome. Within 1-12 wk aftertransmission patients demonstratefever,
malaise, skin rash, lymphadenopathy, aseptic meningitis, and occasionally symp-
toms of encephalopathy. There is an initial fall in theT4/T8 ratio, and atypical lym-
phocytes are common. This syndrome in many ways resembles infection with EBV
and CMV. Virus can be isolated from the blood for 2-3 wk, during which period
antiviral antibodies are absent. After this time an immune response to the virus
occurs, andboth cytotoxiclymphocytes specific forvirus-infected targets and specific
antibodies appear. Initially, antibodies of the IgM classpredominate, followed by IgG.
It is possible that infection occurs within the central nervous system during the
early phases ofthe disease. Some believe that infected Tblasts may enterthecentral
nervoussystem (CNS), even passing across the bloodbrainbarrier. Brainendothelial
cells contain viral products, although no CD4 antigencan be demonstrated on their
surfacemembranes. Considerable evidence suggests that macrophages, presumably
derivedfrom infected monocytes, are an important source of CNS virus. Theseelon-
gate, stellate microgliahave recently been shown to be widely distributed in thebrain
and they can express CD4 virus receptors. The wide secretory repertoire of these
cells may contribute to normal brain function, while macrophage infection could2418
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lead to functional abnormalities, perhaps ofa reversible nature. This would be in
keeping with the ability ofAZT to reverse the servere symptoms ofAIDS encepha-
lopathy.
2. Bone Marrow Involvement.
￿
Little is known about the ability of HIV to enter
and replicate within bone marrow cells, including multipotential and committed
precursorpopulations and the more mature elements. One would expect that bone
marrow depression is the causeofthe pancytopenia seen in AIDS patients, but factors
other than direct HIV infection of precursor cells may be involved. These would
include parasitization by secondary invaders such asMycobacteriumintracellulare, which
takeup residence within bonemarrowmacrophages and thereby alterthe formation
of growth factors.
3. T Cells and Lymphoid Organs.
￿
See next section.
Session II.- Human T Cell Dynamics. Chairmen. A. Fauct and I. Weissman
A. Frequency of HIVinfected T Cells
Thedifficulty in identifyingproductively infected Tcells by in situ hybridization
of bulk leukocytes from blood and lymphoid tissues is well known. Data with the
polymerase chain reaction to quantify levels of HIV DNA are eagerly awaited. It
remains unclearifthere are latent or persistent states ofHIV infection in primary
human T cells, i.e., integrated or unintegrated proviral DNA that is not expressed
or expressed at very low levels .
T cell and monocyte cell lines have been isolated that carry a latent form ofHIV
Activation occurs withIUdRor withcertain cytokines(TNF/cachectin, lymphotoxin,
granulocyte/macrophage colony-stimulating factor [GM-CSF]). The possibility was
raised that latent HIV in cell lines may represent defective provirus.
B. Mechanisms for CD4+ T Cell Depletion
The earliestview ofmechanism was the followingsequence: (a) many Tcellscarry
latent HIV, (b) both T cell and HIV are activated upon antigen encounter, and (c)
T cell death ensues because of the cytopathic infection. Nevertheless, since so few
T cellsmay beinfected, therecould be other important mechanisms wherebyexten-
sive, prolonged, and often irreversible CD4+ lymphocyte depletion occurs. The fol-
lowing mechanisms were considered.
1. SyncytiumFormation.
￿
Infrequent, infected cells express gp120 upon activation .
These fuse to large numbers ofCD4+ uninfected cells, and in 3-24 h the syncytia
die. It has been difficult to identify syncytia in situ, with the exception of macro-
phage giant cells in the brain, and syncytia are not readily detected in productively
infected primary cells in vitro. Many of the studies on syncytium formation have
used CD4+ cell lines rather than primary, resting CD4+ lymphocytes.
2. Direct Cytotoxiciy.
￿
Individual cells may swell and die in cultures of blood
mononuclearcells, orin celllines carrying HIV mutants that are genetically unable
to form syncytia. Toxicity may require gp120, but as core particles.
3. Autoimmuniy.
￿
Antibodies to p18, a protein found on the surface of activated
CD4+ lymphocytes, may mediate cell death by antibody-dependent cell-mediated
cytotoxicity (ADCC). Arguingagainst the generality ofthis mechanismare patients,
who when given AZT or other chain terminators, show a marked increase in CD4+
T cells and function within 2 wk oftherapy.COHN AND STEINMAN
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4. Loss ofa CD8' Regulator Cell.
￿
The existence of such cells was suggested by
studies ofpatients who expressed HIV in culture only ifthe CD8' subset was sub-
stantially depleted. When CD8' and CD4+ subsets have been separated by a 0.45-
pm filter, the CD8' cell still reduced production of HIV from the CD4+ subset.
However, CD8' cell supernatants do not suppress infection, suggesting a labile
factor. The CD8' subset does not reduce CD4+ cell numbers or proliferative func-
tion, and does not seem to require matching at HLA. The CD8' cells suppress
HIV production from macrophages as well.
5. Increased VirulenceoftheHIVIsolatewith Time.
￿
This hasbeen reportedin asmall
sample ofpatients. This may represent mutation ofan initial isolate, or outgrowth
of a new isolate.
6. TransferofHIVfrom InfectedDendritic Cells to TCells.
￿
Dendritic cells are special-
ized to migrate from nonlymphoid tissues to the T areas oflymphoid organs, and
to form stable aggregates with immunologically active lymphocytes. These proper-
ties may provide a physiologic pathway for T cell sensitization to antigens that have
been deposited in tissues. Given the evidence that dendritic cells may be infected
with HIV (Session I), these cellsmightserveas a reservoir toinfect Tcells whenever
called upon to present antigen in situ.
C. Thymus Function
Beyond the possible pathways for T cell depletion in AIDS (above), there is the
added unknown concerning the capacity of HIV patients to produce new T cells.
It hasbeen difficultto study thymus function in man and inAIDS, butthe pathway
for thympoiesis is being outlined in rodents.
The CD4 antigen is expressed relatively late in Tcell development. Mousebone
marrow contains clonogenic thymocyte precursors at a frequency of 1/36,000. The
majority have the phenotype Thy-11°`" lineage `g (negative for CD4, CD8, CD11b,
and a granulocyte antigen). 25-30 of these cells, isolated on a FACS, reconstitute
all cell lineages in irradiated mice. New "stem cell antigens" are being identified.
One mAb, SCA-1, can be used to further enrich the bone marrow progenitor. In
rats exposed to 300 rad ofionizing irradiation, most regenerating thymocytes pass
through a short-lived (<1 d) CD4-CD8+ stage. At least 50% of normal
CD4-CD8+ 0X44- thymocytes also can be pulse labeled with BUdR, and within
16 h most became CD4+CD8* in vitro.
SIVinfection inprimatesmightprovidean opportunityto studythymus function
in immunodeficiency. A novel mouse model was also described. Mice with severe
combined immunodeficiency (SCID mice)lack B and T lymphocytes, and interest-
ingly, succumb to Pneumocystis carinii pneumonia. The health of SCID mice can be
improvedwith grafts ofhuman fetalliver and thymus, and the mice can be returned
to a conventional animal facility. The human thymus develops beneath the kidney
capsule and contains human thymocytes, both human and mouse dendritic cells,
as wellashumanclassII-positive cortical epithelium. Human Tcells are also found
in the blood, but mysteriously, few are noted in peripheral lymphoid organs.
Session III. VaccinesandProtective Immunity. Chairmen: H. KoprowskiandR. Lerner
Thedevelopment ofvaccines towards many infectious agents has depended upon
the availability ofanimal models, andthe induction ofneutralizing antibodies. How-
ever, there are examples ofvaccines that are effective in laboratory animals but not2420
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inthe relevant animal in thewild, andthere havebeen vaccines to rabies and Herpes
simplex that do not seem to elicit much neutralizing antibody. Possibly, protective
T cells are induced in the latter situations. Also it is not clear why some vaccines,
e.g., yellow fever, induce such long-lasting immunity.
The design ofvaccines depends upon information on pathogenesis (Session I).
For HIV, one unknown is the extent to which cell-free virus is needed to establish
infection. If cell-associated virus is critical, the demands of an antibody-based vac-
cineincrease sinceone must design neutralizing antibodiesthatblock cell-cell trans-
mission andnot thepenetration offreevirus intocells. Anotherunknown is whether
there are T cell-dependent resistance mechanisms. Both proliferative and cytotoxic
T cells are being detected as part ofthe response to HIV in man and experimental
animals. Their role in eliminating infected macrophages and dendritic cells for in-
stance is not clear and will be difficult to evaluate without animal models.
Many aspects ofvaccination were discussed in and outside ofthe sessions. Three
topics are expanded here.
A. T Cell Epitopes
The predictive value ofthe Berzofsky/DeLisi model, in which sequences capable
of forming amphipathic double helices act as helper T cell epitopes, was summa-
rized for the malaria circumsporozoite protein. Therewere fivemajorpredictedsites,
correspondingto about one-third ofthe protein. Four were found to stimulate blood
leukocytes from donors in the endemic regions ofGambia. 24 other peptides were
tested and were not Tcell stimulatory. A candidate Tcell stimulatoryepitopeoccurs
on a polymorphic region of the circumsporozoite protein.
Two peptides were selected from the conserved regions ofHIV gp120. Both could
form amphipathic helices and were nonglycosylated. The peptides would immunize
mice, as assessed byT cellproliferative responses, and therewere clear MHC-restricted
responder and nonresponder mouse strains. One peptide also stimulated prolifera-
tion in cells from patients who had been immunized in Zaire with vaccinia-HIV
env recombinants.
CTL epitopes in the HIVenv protein also are being analyzed in mice. Mice have
been immunized with vaccinia-env recombinants, boosted in vitro with cell lines
expressing VAC-env, and then tested for CTL activity against a panel ofpeptides
on 3T3 (H-2d) or L cell (H-2k) targets. H-2d mice were high responders to vaccinia-
gp 160, while H-2k were low. A large number ofpeptides, 29 from gp120 and addi-
tional ones from gp41, were tested. Only one was active in H-2d mice (Dd restricted).
This epitope was 308-322 in gp120, which lies in a major neutralizing site for anti-
bodies (see below). The peptide, which has a central R turn, exhibits high variability
when different HIV isolates were examined. If anti-env CTL provide protection
against HIV, this result would imply that there is high mutation in the very region
capable of eliciting B cell and CTL immunity. It will be important to follow this
site longitudinally in HIV isolates. A second feature of the CTL work in mice is
that only one ofthe five mouse class I molecules that were tested could present HIV
gp120, but other HIV gene products need to be evaluated.
The tight restriction imposed by the MHC on antigen presentation was illustrated
as well bydata on murine lymphocyticchoriomeningitis virus (LCMV). Inbred mice
were immunized with vaccinia-glycoprotein or vaccinia-nucleoprotein. H-2' and
H-29 had high levels of CTL to nucleoprotein, and to the same NP peptide, butCOHN AND STEINMAN
￿
2421
only H-2b made CTL to glycoprotein. Mice could beprotected against a lethal chal-
lenge by NP immunization. No neutralizing antibody was detected, just CTL.
Several groups have detected CTL from HIVinfected patients, most readily in
patients who were not in the AIDS phase ofthe disease. The cells are capable of
lysing syngeneic targets. HIV-specific and MHC-restricted activities have been de-
tected. These CTL have been found in fresh blood, suggesting a significant persis-
tent antigen load in situ.
B. Neutralizing Antibodies
HIV infection is notable for the very low ratio of neutralizing to total antigen-
bindingantibodies. There seem to betwo sites on the gp120 molecule to which anti-
bodies might be neutralizing, especially for free HIV virions. One is at 400-434,
a highly conserved (HIV-1 and -2, SIV) region in gp120 that is involved in binding
ofgp120 to CD4and is glycosylated. The other site is at 300-330 and is highly vari-
able (see above). Antibodies to this latter site can neutralize after HIV binding and
seem able to block fusion as well as syncytium formation. Seropositive individuals
form little antibody to this site, but four experimental mAbs have now been raised.
Studies arein progress ofthe antibodiesthat aredeveloping inalaboratory worker
who was infected with HIV. The worker formed type-specific neutralizing antibodies
tothe 300-330 site. Theseantibodies could beblockedwith a 24-amino acid peptide
from this region. A year later, more crossreactive antibodies were formed to other
gp120 sites. These antibodies could block gp120-CD4 binding and so presumably
reacted with the 400-434 site. The HIV isolates from the worker are now showing
variation in the 300-330 site, whichmight allow escape from type-specificneutralizing
antibodies. It has not been determined ifone clone of HIV is generating variants,
or if there is selection of a different initial isolate.
C. Chimpanzee-HIV Studies
Chimps were passively immunized with a pool ofhyperimmune human Ig con-
taining broadly crossreactiveneutralizingantibodies. These blocked binding, or the
gp120/CD4 interaction, but not fusion. The chimps were immediately challenged
with a cloned isolate ofHIV intramuscularly. Circulating antibodies were evident
at day 3, but only low titers at day 7. The short life span of the antibodies might
reflectaggregation ofthe initial IgGinoculum. Also, it is not clearifantibodies were
present at the intramuscular injection site. In any case, the passive immunization
did not reduce infection with HIV. One unknown in the HIV-Chimp model is that
while theleukocyteoftheseprimates can beinfected invitrowith HIV, forunknown
reasons chimps are protected from acquiring AIDS in situ.
D. Summary
in spite ofmuch ongoing experimentation, the consensus view is that a vaccine
will be difficult to achieve. New strategies ofchemo- and immunotherapy may bear
more rapid results.
Session IV Therapeutic Consideration. Chairmen: Martin Hirsch and Barry Bloom
A. Antiviral Chemotherapy
Infection with HIV involves several discrete steps, someofwhich are being evalu-
ated as possible targets for antiviral chemotherapy. These include:2422
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Binding of virus to target cell (soluble CD4, dextran sulfate, antibodies)
Fusion of viral membrane to host cell membrane
Viral penetration and uncoating
Reverse transcriptase (AZT, ddC, ddA, adenollene, cytallene)
Degradation of RNA by RNase
Integration of DNA into host genome
Transcription and post-transcriptional enhancers (tat, art)
Ribosomal frameshifting and proteolysis of polyprotein precursors
Viral component production and assembly (castanospermine).
A review of the current National Institutes of Health chemotherapy program in-
dicates that -30 drugs that have in vitro anti-HIV activity are under test in vivo.
There are 35 funded Institutional programs, 27 protocol trials using 17 agents of
which 9 are antiviral, 4 are biological response modifiers, and 5 are against oppor-
tunistic disease. The program is being carried out in an atmosphere of public pres-
sure and in whichthere is extensive availability of selected agents in ablack market.
AZT is the most widely used agent and it has resulted in 75% survival at 21 mo.
Its use is complicated by severe bone marrow depression and transfusion require-
ments in some patients. 2'-dideoxycytidine also appears to be virustatic without
significant bone marrow depression, but its use may be complicated by severe pe-
ripheral neuropathy. Significant reduction in p24 antigen occurs in approximately
half the patients receiving the drug over a 30-wk course.
It is of interest that the dementia of AIDS appears to be reversible if patients are
treated early with AZT. After a 6-wk course of therapy, CAT scans reveal a reduc-
tion in ventricular size; brainglucose utilization is increased, and psychometrics are
improved. AZT is known to enter the CSF, with an accompanying reduction in the
amount of p24 antigen in the CSR Chemoprophylaxis is now being evaluated in
asymptomatic seropositive patients.
Newer nucleoside analogs, which have cyclic 4 carbon chains instead of sugars
(adenollene and cytallene) show promise in their abilityto protect tissue culture cells
(the ATH8 cell line) at 0.5-50 gm. Synthetic oligonucleotides with sulfur vs. oxygen
groups could represent useful, long-lived antisense reagents. The general consensus
is that chemotherapeutic breakthroughs will not occur in the near future.
B. Immunotherapeutics
The newer recombinant cytokines and lymphokines are under study alone or in
combination with AZT. These agents such as IL-2, IFN-a, IFN-'Y, and GM-CSF
are administered by theparenteral routein an attempt to replacetheproducts manufac-
tured by the defieient CD4+ T cells. The use of GM-CSF with AZT is also an at-
temptto protect the bone marrow. One target of these agents is the parasitized mac-
rophage. These cells, in the absence of helper T cells, fail to become activated and
are permissive hosts for a variety of opportunistic invaders that ultimately lead to
the death of AIDS patients. The results of clinical trials should become available
within the year.
Soluble CD4 molecules can inhibit viral infection in vitro at levels of 5 Pg/ml.
Currentstudies areusingvarioussegments ofthe CD4molecule attached to cytotoxins
and antibodies to seek out gp120-expressing targets. Primates are able to tolerate
CD4 at levels of 10-25 ug/ml, but the ability of the molecule to protect primates
from infection is unknown at this time.Participants
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